Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2361 to 2370 of 2581 total matches.

Yosprala - A Combination of Aspirin and Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
. Primary prevention of ulcers in patients taking aspirin or NSAIDs. Med Lett Drugs Ther 2010; 52:17. 3 ...
The FDA has approved Yosprala (Aralez), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, for secondary prevention of cardiovascular and cerebrovascular events in patients who are at risk of developing aspirin-associated gastric ulcers (≥55 years old or history of gastric ulcers). Yosprala is the first product to become available in the US that combines aspirin and a proton pump inhibitor (PPI).
Med Lett Drugs Ther. 2017 Jan 30;59(1513):25-6 |  Show IntroductionHide Introduction

COVID-19 Update: Novavax Vaccine Authorized for Booster Immunization (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
; 398:2258. 4. COVID-19 Update: FDA authorizes Novavax COVID-19 vaccine. Med Lett Drugs Ther 2022; 64 ...
The FDA has expanded its Emergency Use Authorization for the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax to include its use as a first booster dose in adults who completed a primary series with any COVID-19 vaccine ≥6 months previously and are unable or unwilling to receive a booster dose of a bivalent mRNA vaccine. The Novavax vaccine is not authorized for use in persons who have received a booster dose of any other COVID-19 vaccine.
Med Lett Drugs Ther. 2022 Oct 31;64(1662):e1-2 |  Show IntroductionHide Introduction

Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
has no pronunciation or meaning; such suffixes are added to biologic drugs to distinguish reference products ...
Remestemcel-L (Ryoncil – Mesoblast), an allogeneic bone marrow-derived mesenchymal stromal cell therapy, has been approved by the FDA for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in patients ≥2 months old. Steroid-refractory GVHD is associated with a poor prognosis, organ damage, and death, particularly in pediatric patients. Remestemcel-L is the first cellular therapy to be approved in the US for this indication and the only treatment of any kind to be approved for GVHD in children <12 years old.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):e36-7   doi:10.58347/tml.2025.1722i |  Show IntroductionHide Introduction

In Brief: A New Indication for Tenecteplase (TNKase)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
for reconstitution. The drug should be administered as a single IV bolus dose over 5 seconds as soon as possible ...
The tissue plasminogen activator (tPA) tenecteplase (TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this indication; alteplase (Activase) was approved in 1996. Tenecteplase was approved in 2000 to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2   doi:10.58347/tml.2025.1727d |  Show IntroductionHide Introduction

NovolinPen for Insulin Injection

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The NovolinPen (Squibb - Novo) is a device that uses prefilled cartridges to inject semisynthetic human insulin (Medical Letter, 25:63, 1983). Three formulations are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70% NPH and 30% regular (Novolin 70/30 PenFill). The NovolinPen is advertised as more accurate, more convenient and less expensive than conventional syringes and needles. The same device is marketed in Canada as the Novolin-Pen II (Connaught Novo). (An earlier device is also available as the Novolin-Pen in Canada and the...
Med Lett Drugs Ther. 1988 Dec 30;30(782):117-8 |  Show IntroductionHide Introduction

Laparoscopic Cholecystectomy

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990  (Issue 834)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Unlike new drugs, new techniques for surgery do not need the approval of any government agency. Laparoscopic cholecystectomy, made possible by the development of miniaturized television cameras, is one such technique that has recently attracted widespread interest (LW Way, N Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).
Med Lett Drugs Ther. 1990 Dec 28;32(834):115-6 |  Show IntroductionHide Introduction

Home Testing of Cholesterol

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 1994  (Issue 932)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The new Advanced Care Cholesterol Test (Johnson & Johnson) now being advertised to the general public encourages patients to test their own serum cholesterol concentrations. Approved by the US Food and Drug Administration, this product is available in pharmacies without a prescription at a cost of about $20 for a single determination.
Med Lett Drugs Ther. 1994 Sep 30;36(932):85-6 |  Show IntroductionHide Introduction

Salt Restriction

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2012  (Issue 1384)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 13 The Medical Letter® On Drugs ...
The average daily intake of sodium in the US is about 3400 mg. Dietary guidelines recommend reducing it to <2300 mg/day in general, and to 1500 mg for African Americans, persons with hypertension, diabetes or chronic renal disease, and for all those >50 years old. Salt reduction lowers blood pressure, and lowering blood pressure reduces the risk of myocardial infarction, stroke and death.
Med Lett Drugs Ther. 2012 Feb 20;54(1384):13 |  Show IntroductionHide Introduction

Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2013  (Issue 1420)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1420) July 8, 2013 ...
The FDA has approved use of Kcentra (CSL Behring), a human-derived 4-factor prothrombin complex concentrate (PCC), for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. It is the only 4-factor PCC available in the US.
Med Lett Drugs Ther. 2013 Jul 8;55(1420):53-4 |  Show IntroductionHide Introduction

Auvi-Q Epinephrine Auto-Injector Returns

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017  (Issue 1515)
Drug Formulations1 Cost2 Epinephrine injection, USP – generic (Mylan)3 0.15 mg/0.3 mL, $300.00 0.3 ...
Auvi-Q (Kaléo; previously manufactured and marketed by Sanofi), the epinephrine auto-injector approved by the FDA in 2012 for emergency treatment of anaphylaxis and voluntarily withdrawn in 2015 due to potential inaccurate dosage delivery, has become available once more. According to Kaléo, improvements in the manufacturing process have addressed the concerns that led to its recall.
Med Lett Drugs Ther. 2017 Feb 27;59(1515):33 |  Show IntroductionHide Introduction